MicroPort Scientific Corp. (HK:0853)
:0853
Want to see HK:0853 full AI Analyst Report?
Top Page
MicroPort Scientific
(0853)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$7.50
▼(-35.73% Downside)
Action:Reiterated
Date:05/04/26
The score is held back primarily by weak cash generation (still negative free cash flow) and a bearish technical setup (below key moving averages with negative MACD). These are partly offset by improved profitability versus prior years and a low P/E valuation.
Positive Factors
Profitability turnaround
A return to accounting profitability and a near-10% EBITDA margin indicate the company has passed key operational inflection points. Sustained net income supports reinvestment, debt servicing, and strategic R&D/market initiatives if margins and revenue stabilize, improving long-term resilience.
Negative Factors
Weak free cash flow
Persistently negative free cash flow means accounting profits haven't translated into cash available for growth, paydown, or distributions. Continued negative FCF constrains strategic flexibility and raises reliance on financing, making sustained investment or deleveraging harder over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability turnaround
A return to accounting profitability and a near-10% EBITDA margin indicate the company has passed key operational inflection points. Sustained net income supports reinvestment, debt servicing, and strategic R&D/market initiatives if margins and revenue stabilize, improving long-term resilience.
Read all positive factors
MicroPort Scientific (0853) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$14.78B
Dividend YieldN/A
Average Volume (3M)25.37M
Price to Earnings (P/E)6.0
Beta (1Y)1.71
Revenue Growth-3.62%
EPS GrowthN/A
CountryHK
Employees6,347
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.02
Shares Outstanding1,917,372,700
10 Day Avg. Volume21,967,342
30 Day Avg. Volume25,373,873
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)2.65
Price to Sales (P/S)2.61
P/FCF Ratio-33.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$16.05Price Target Upside37.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.05
Revenue Forecast (FY)HK$1.18B
MicroPort Scientific Business Overview & Revenue Model
Company Description
MicroPort Scientific Corporation, an investment holding company, manufactures, and markets, and distributes medical devices in the People's Republic of China, North America, Europe, other Asian countries, South America, and internationally. The co...
How the Company Makes Money
MicroPort makes money primarily by selling medical devices and related products to hospitals, clinics, and healthcare distributors. Its core revenue streams typically come from: (1) cardiovascular intervention products (e.g., interventional consum...
MicroPort Scientific Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
52
Neutral
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 996.38M | 1.03B | 950.73M | 840.83M | 778.64M |
| Gross Profit | 554.33M | 574.09M | 532.10M | 501.77M | 491.77M |
| EBITDA | 88.83M | -45.30M | -382.54M | -430.26M | -256.35M |
| Net Income | 48.59M | -214.04M | -477.63M | -436.51M | -276.48M |
Balance Sheet | |||||
| Total Assets | 3.70B | 3.63B | 3.93B | 3.99B | 4.38B |
| Cash, Cash Equivalents and Short-Term Investments | 813.82M | 974.48M | 1.06B | 1.24B | 1.75B |
| Total Debt | 1.60B | 1.69B | 1.70B | 1.47B | 1.24B |
| Total Liabilities | 2.20B | 2.49B | 2.53B | 2.20B | 2.16B |
| Stockholders Equity | 980.69M | 603.47M | 757.82M | 1.14B | 1.49B |
Cash Flow | |||||
| Free Cash Flow | -77.73M | -158.10M | -430.99M | -600.58M | -505.45M |
| Operating Cash Flow | 9.21M | -49.67M | -231.87M | -343.30M | -257.53M |
| Investing Cash Flow | 98.29M | -149.73M | -376.81M | -412.75M | -655.74M |
| Financing Cash Flow | -151.39M | -97.92M | 434.90M | 273.00M | 1.66B |
MicroPort Scientific Technical Analysis
Negative
11.67
Price Trends
9.18
Negative
10.26
Negative
11.41
Negative
Market Momentum
-0.43
Positive
29.13
Positive
15.26
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0853, the sentiment is Negative. The current price of 11.67 is above the 20-day moving average (MA) of 8.49, above the 50-day MA of 9.18, and above the 200-day MA of 11.41, indicating a bearish trend. The MACD of -0.43 indicates Positive momentum. The RSI at 29.13 is Positive, neither overbought nor oversold. The STOCH value of 15.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0853.
MicroPort Scientific Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$1.81B | 21.92 | 7.53% | ― | 47.07% | ― | |
68 Neutral | HK$9.20B | 42.46 | 4.02% | ― | 5.10% | -32.48% | |
59 Neutral | HK$2.82B | 31.09 | 7.22% | ― | 20.65% | 127.07% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$3.49B | -17.66 | -11.27% | ― | 16.35% | 9.84% | |
49 Neutral | HK$160.74M | -2.82 | -17.70% | ― | -38.20% | -108.24% | |
48 Neutral | HK$14.78B | 6.01 | 6.07% | ― | -3.62% | ― |
* Healthcare Sector Average
HK:0853
MicroPort Scientific
7.71
1.14
17.35%
HK:9996
Peijia Medical Ltd.
5.21
-0.54
-9.39%
HK:6669
Acotec Scientific Holdings Limited
9.01
0.57
6.75%
HK:1302
LifeTech Scientific Corporation
2.13
0.57
36.54%
HK:2393
Yestar Healthcare Holdings Co Ltd
0.07
-0.03
-31.00%
HK:6609
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
46.60
19.00
68.84%
MicroPort Scientific Corporate Events
MicroPort’s Endovastec Unit Delivers Strong Q1 2026 Earnings Lift
Apr 29, 2026
Shanghai MicroPort Endovascular MedTech, the 40.32%-owned endovascular unit of MicroPort Scientific, reported double-digit growth for the first quarter of 2026, underscoring resilient demand for its vascular intervention products. Revenue for the ...
MicroPort Sets Up Global Executive Committee and Reshapes Top Management Roles
Mar 31, 2026
MicroPort Scientific has created a Global Executive Committee as it deepens its international presence and seeks to improve coordination across its worldwide operations. The committee will include the rotating chief executive officer, chief financ...
MicroPort Returns to Profitability as Platform Strategy and Cardiac Portfolio Drive New Growth
Mar 31, 2026
MicroPort Scientific has returned to profitability for the year ended 31 December 2025, posting net profit of US$38.4 million as revenue grew 6% and gross profit rose 10.5%. Non-GAAP operating profit swung from a loss to a small profit and operati...
MicroPort Scientific Appoints New Company Secretary and Authorised Representative
Mar 31, 2026
MicroPort Scientific Corporation has announced a senior corporate governance change, with company secretary and authorised representative Ms. Yuen Wing Yan Winnie stepping down effective 31 March 2026, after confirming she has no disagreement with...
MicroPort Unit Endovastec Posts Double‑Digit Revenue and Earnings Growth in 2025
Mar 30, 2026
Shanghai MicroPort Endovascular MedTech, 40.32% owned by MicroPort Scientific and consolidated into its accounts, reported audited revenue of RMB1.35 billion for the twelve months ended 31 December 2025, up 12% year on year, with net profit attrib...
MicroPort Sets March 31 Board Meeting to Approve 2025 Final Results
Mar 19, 2026
MicroPort Scientific Corporation has scheduled a board meeting for 31 March 2026 to review and approve the group’s audited financial results for the year ended 31 December 2025. The meeting will also address other corporate matters, signalin...
MicroPort Unit Endovastec Posts Double-Digit Revenue and Earnings Growth in 2025
Feb 27, 2026
Shanghai MicroPort Endovascular MedTech (Endovastec), 40.32% owned by MicroPort Scientific, reported unaudited revenue of RMB1.35 billion for the twelve months ended 31 December 2025, up 12% year on year. Net profit attributable to Endovastec̵...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.